TABLE 6.

Relationship between antifungal susceptibility results and prognosis in 110 cryptococcal meningitis subjects.

Treatment regimen	Total	Survival (No. %)	Dead (No. %)	p-value
Amphotericin B containing regimen	84	64 (76.2)	20 (23.8)	0.588
WT	79	61 (77.2)	18 (22.8)
Non-WT	5	3 (60.0)	2 (40.0)
5-Flucytosine containing regimen	52	41 (78.8)	11 (21.2)	0.193
WT	48	39 (81.2)	9 (18.8)
Non-WT	4	2 (50)	2 (50)
Fluconazole containing regimen	57	44 (77.2)	13 (22.8)	0.034#
WT	53	43 (81.1)	10 (18.9)
Non-WT	4	1 (25.0)	3 (75.0)
Amphotericin B, fluconazole combined with 5-flucytosine	29	25 (86.2)	4 (13.8)	0.553
WT	24	21 (87.5)	3 (22.5)
Non-WT to any of amphotericin B, fluconazole, and 5-flucytosine	5	4 (80.0)	1 (20.0)
Amphotericin B combined with fluconazole	23	16 (69.6)	7 (30.4)	0.067
WT	19	15 (78.9)	4 (21.1)
Non-WT to amphotericin B or/and fluconazole	4	1 (25.0)	3 (75.0)
Amphotericin B combined with 5-flucytosine	21	16 (76.2)	5 (23.8)	0.429
WT	19	15 (78.9)	4 (21.1)
Non-WT to amphotericin B or/and 5-flucytosine	2	1 (50.0)	1 (50.0)
Fluconazole combined with 5-flucytosine	2	0	2 (100)	/
WT	1	0	1 (100)
Non-WT to fluconazole or/and 5-flucytosine	1	0	1 (100)

WT, wild-type; Non-WT, non-wild-type. ^#p < 0.05.